Live Breaking News & Updates on Quarter For Kalvista Pharmaceuticals

Stay updated with breaking news from Quarter for kalvista pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Benjamin L. Palleiko Sells 4,037 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CFO Benjamin L. Palleiko sold 4,037 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total value of $40,935.18. Following the completion of the transaction, the chief financial officer now directly owns 78,126 […] ....

Hong Kong , Benjaminl Palleiko , Cantor Fitzgerald , Kalvista Pharmaceuticals Inc , Jpmorgan Chase Co , Hong Kong Ltd , Quarter For Kalvista Pharmaceuticals , Institutional Investors Weigh In On Kalvista Pharmaceuticals , Pricet Rowe Associates Inc , Kalvista Pharmaceuticals , News Ratings For Kalvista Pharmaceuticals Daily , Kalvista Pharmaceuticals Stock Performance , Needham Company , Get Rating , Vista Pharmaceuticals , Kong Ltd , Kalvista Pharmaceuticals Daily , Nasdaq Kalv , Insider Trading , Nsider Trades ,

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Benjamin L. Palleiko Sells 4,037 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CFO Benjamin L. Palleiko sold 4,037 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $10.14, for a total value of $40,935.18. Following the sale, the chief financial officer now directly owns 78,126 shares in the company, […] ....

New York , United States , Benjaminl Palleiko , Kalvista Pharmaceuticals Company Profile , Kalvista Pharmaceuticals Inc , First Manhattan , Cantor Fitzgerald , Quarter For Kalvista Pharmaceuticals , Needham Company , Saturnv Capital Management , Kalvista Pharmaceuticals , Squarepoint Ops , Kalvista Pharmaceuticals Trading , Securities Exchange Commission , Jpmorgan Chase Co , News Ratings For Kalvista Pharmaceuticals Daily , Get Rating , Exchange Commission , Vista Pharmaceuticals , Street Corp , Kalvista Pharmaceuticals Daily , Nasdaq Kalv , Insider Trading , Nsider Trades ,

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Thomas Andrew Crockett Sells 5,627 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CEO Thomas Andrew Crockett sold 5,627 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $10.14, for a total transaction of $57,057.78. Following the completion of the sale, the chief executive officer now owns 128,050 shares […] ....

United Kingdom General , United Kingdom , Thomas Andrew Crockett , Kalvista Pharmaceuticals , Institutional Trading Of Kalvista Pharmaceuticals , York Mellon Corp , News Ratings For Kalvista Pharmaceuticals Daily , Securities Exchange Commission , Blackrock Inc , Jpmorgan Chase Co , Kalvista Pharmaceuticals Stock Performance , Metlife Investment Management , Kalvista Pharmaceuticals Inc , Kalvista Pharmaceuticals Company Profile , Quarter For Kalvista Pharmaceuticals , Needham Company , Cantor Fitzgerald , Get Rating , Andrew Crockett , Exchange Commission , Vista Pharmaceuticals , New York Mellon Corp , Life Investment Management , Kalvista Pharmaceuticals Daily , Nasdaq Kalv , Insider Trading ,

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Christopher Yea Sells 2,604 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) insider Christopher Yea sold 2,604 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total value of $26,404.56. Following the sale, the insider now directly owns 37,310 shares of the company’s stock, valued […] ....

Tang Capital Management , Kalvista Pharmaceuticals Inc , Needham Company , Quarter For Kalvista Pharmaceuticals , Kalvista Pharmaceuticals Price Performance , Cantor Fitzgerald , Vr Adviser , Boxer Capital , Kalvista Pharmaceuticals , Jefferies Financial Group Inc , Frazier Life Sciences Management , Institutional Trading Of Kalvista Pharmaceuticals , News Ratings For Kalvista Pharmaceuticals Daily , Securities Exchange Commission , Get Rating , Christopher Yea , Exchange Commission , Vista Pharmaceuticals , Capital Management , Jefferies Financial Group , Kalvista Pharmaceuticals Daily , Nasdaq Kalv , Insider Trading , Nsider Trades ,

Denali Advisors LLC Buys New Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Denali Advisors LLC bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $73,000. A number of other hedge funds also recently added […] ....

Hong Kong , United States , Thomas Andrew Crockett , Benjaminl Palleiko , Cantor Fitzgerald , Kalvista Pharmaceuticals Company Profile , Pricet Rowe Associates Inc , America Corp , Kalvista Pharmaceuticals Inc , Denali Advisors , Hong Kong Ltd , Needham Company , Jpmorgan Chase Co , Securities Exchange Commission , Quarter For Kalvista Pharmaceuticals , News Ratings For Kalvista Pharmaceuticals Daily , Kalvista Pharmaceuticals , Kalvista Pharmaceuticals Price Performance , Get Rating , Kong Ltd , Exchange Commission , Andrew Crockett , Vista Pharmaceuticals , Visit Holdingschannel , Kalvista Pharmaceuticals Daily , Nasdaq Kalv ,